1. Home
  2. KREF vs DCTH Comparison

KREF vs DCTH Comparison

Compare KREF & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KKR Real Estate Finance Trust Inc.

KREF

KKR Real Estate Finance Trust Inc.

HOLD

Current Price

$6.51

Market Cap

399.8M

Sector

Real Estate

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$11.50

Market Cap

363.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KREF
DCTH
Founded
2014
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical/Dental Instruments
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
399.8M
363.5M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
KREF
DCTH
Price
$6.51
$11.50
Analyst Decision
Hold
Strong Buy
Analyst Count
6
4
Target Price
$7.88
$22.00
AVG Volume (30 Days)
1.3M
252.6K
Earning Date
04-22-2026
05-07-2026
Dividend Yield
6.49%
N/A
EPS Growth
N/A
107.53
EPS
N/A
0.07
Revenue
N/A
N/A
Revenue This Year
$545.92
$24.54
Revenue Next Year
N/A
$33.15
P/E Ratio
N/A
$157.36
Revenue Growth
N/A
N/A
52 Week Low
$5.25
$8.12
52 Week High
$9.98
$18.23

Technical Indicators

Market Signals
Indicator
KREF
DCTH
Relative Strength Index (RSI) 52.26 66.38
Support Level $5.87 $10.50
Resistance Level $6.90 $11.99
Average True Range (ATR) 0.24 0.41
MACD 0.02 0.02
Stochastic Oscillator 74.85 96.68

Price Performance

Historical Comparison
KREF
DCTH

About KREF KKR Real Estate Finance Trust Inc.

KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: